FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030536448> ?p ?o ?g. }

• W2030536448 endingPage "1105" @default.
• W2030536448 startingPage "1097" @default.
• W2030536448 abstract "NKX3.1 is a prostatic tumor suppressor gene located on chromosome 8p. Although most studies have shown that staining for NKX3.1 protein is positive in the majority of primary prostatic adenocarcinomas, it has been shown to be downregulated in many high-grade prostate cancers, and completely lost in the majority of metastatic prostate cancers (eg, in 65% to 78% of lesions). A recent study showed that NKX3.1 staining with a novel antibody was highly sensitive and specific for high-grade prostatic adenocarcinoma when compared with high-grade urothelial carcinoma. This raised the question that this antibody may perform better than earlier used antibodies in metastatic prostate tumors. However, the sensitivity and specificity for prostate carcinomas for this antibody in metastatic lesions was not determined. Although prostate-specific antigen (PSA) and prostatic-specific acid phosphatase (PSAP) are excellent tissue markers of prostate cancer, at times they may be expressed at low levels, focally, or not at all in poorly differentiated primary and metastatic prostatic adenocarcinomas. The purpose of this study was to determine the performance of NKX3.1 as a marker of metastatic adenocarcinoma of prostatic origin. Immunohistochemical staining against NKX3.1, PSA, and PSAP was carried out on a tissue microarray (TMA) (0.6-mm tissue cores) of hormone naïve metastatic prostate adenocarcinoma specimens from lymph nodes, bone, and soft tissue. To determine the specificity of NKX3.1 for prostatic adenocarcinoma, we used TMAs that contained cancers from various sites including the urinary bladder, breast, colon, salivary gland, stomach, pancreas, thyroid, and central nervous system, and standard paraffin sections of cancers from other sites including the adrenal cortex, kidney, liver, lung, and testis. Overall 349 nonprostatic tumors were evaluated. Any nuclear staining for NKX3.1 was considered positive and the percentage of cells with nuclear staining and their mean intensity level were assessed visually. Sensitivity was calculated by considering a case positive if any TMA core was positive. The sensitivity for identifying metastatic prostatic adenocarcinomas overall was 98.6% (68/69 cases positive) for NKX3.1, 94.2% (65/69 cores positive) for PSA, and 98.6% (68/69 cores positive) for PSAP. The specificity of NKX3.1 was 99.7% (1/349 nonprostatic tumors positive). The sole positive nonprostatic cancer case was an invasive lobular carcinoma of the breast. NKX3.1 seems to be a highly sensitive and specific tissue marker of metastatic prostatic adenocarcinoma. In the appropriate clinical setting, the addition of IHC staining for NKX3.1, along with other prostate-restricted markers, may prove to be a valuable adjunct to definitively determine prostatic origin in poorly differentiated metastatic carcinomas." @default.
• W2030536448 created "2016-06-24" @default.
• W2030536448 creator A5014785184 @default.
• W2030536448 creator A5019028542 @default.
• W2030536448 creator A5019797870 @default.
• W2030536448 creator A5032487642 @default.
• W2030536448 creator A5048881491 @default.
• W2030536448 creator A5052078144 @default.
• W2030536448 creator A5062227791 @default.
• W2030536448 creator A5077295537 @default.
• W2030536448 creator A5078685340 @default.
• W2030536448 creator A5083333223 @default.
• W2030536448 creator A5084269123 @default.
• W2030536448 date "2010-08-01" @default.
• W2030536448 modified "2023-10-12" @default.
• W2030536448 title "NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors" @default.
• W2030536448 cites W1803194864 @default.
• W2030536448 cites W1966056172 @default.
• W2030536448 cites W1970327509 @default.
• W2030536448 cites W1972912717 @default.
• W2030536448 cites W1982232468 @default.
• W2030536448 cites W1987328113 @default.
• W2030536448 cites W1987368604 @default.
• W2030536448 cites W1995348626 @default.
• W2030536448 cites W1997715784 @default.
• W2030536448 cites W1999070529 @default.
• W2030536448 cites W2004955468 @default.
• W2030536448 cites W2014491165 @default.
• W2030536448 cites W2019845113 @default.
• W2030536448 cites W2027366995 @default.
• W2030536448 cites W2035936829 @default.
• W2030536448 cites W2042204376 @default.
• W2030536448 cites W2052273673 @default.
• W2030536448 cites W2069308519 @default.
• W2030536448 cites W2076720099 @default.
• W2030536448 cites W2078239104 @default.
• W2030536448 cites W2095421687 @default.
• W2030536448 cites W2101703760 @default.
• W2030536448 cites W2109193598 @default.
• W2030536448 cites W2110848383 @default.
• W2030536448 cites W2112336517 @default.
• W2030536448 cites W2127625592 @default.
• W2030536448 cites W2127757047 @default.
• W2030536448 cites W2140649141 @default.
• W2030536448 cites W2144051251 @default.
• W2030536448 cites W2147136637 @default.
• W2030536448 cites W2156289811 @default.
• W2030536448 cites W4297682006 @default.
• W2030536448 cites W4301868850 @default.
• W2030536448 doi "https://doi.org/10.1097/pas.0b013e3181e6cbf3" @default.
• W2030536448 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3072223" @default.
• W2030536448 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20588175" @default.
• W2030536448 hasPublicationYear "2010" @default.
• W2030536448 type Work @default.
• W2030536448 sameAs 2030536448 @default.
• W2030536448 citedByCount "214" @default.
• W2030536448 countsByYear W20305364482012 @default.
• W2030536448 countsByYear W20305364482013 @default.
• W2030536448 countsByYear W20305364482014 @default.
• W2030536448 countsByYear W20305364482015 @default.
• W2030536448 countsByYear W20305364482016 @default.
• W2030536448 countsByYear W20305364482017 @default.
• W2030536448 countsByYear W20305364482018 @default.
• W2030536448 countsByYear W20305364482019 @default.
• W2030536448 countsByYear W20305364482020 @default.
• W2030536448 countsByYear W20305364482021 @default.
• W2030536448 countsByYear W20305364482022 @default.
• W2030536448 countsByYear W20305364482023 @default.
• W2030536448 crossrefType "journal-article" @default.
• W2030536448 hasAuthorship W2030536448A5014785184 @default.
• W2030536448 hasAuthorship W2030536448A5019028542 @default.
• W2030536448 hasAuthorship W2030536448A5019797870 @default.
• W2030536448 hasAuthorship W2030536448A5032487642 @default.
• W2030536448 hasAuthorship W2030536448A5048881491 @default.
• W2030536448 hasAuthorship W2030536448A5052078144 @default.
• W2030536448 hasAuthorship W2030536448A5062227791 @default.
• W2030536448 hasAuthorship W2030536448A5077295537 @default.
• W2030536448 hasAuthorship W2030536448A5078685340 @default.
• W2030536448 hasAuthorship W2030536448A5083333223 @default.
• W2030536448 hasAuthorship W2030536448A5084269123 @default.
• W2030536448 hasBestOaLocation W20305364482 @default.
• W2030536448 hasConcept C121608353 @default.
• W2030536448 hasConcept C126322002 @default.
• W2030536448 hasConcept C142724271 @default.
• W2030536448 hasConcept C193270364 @default.
• W2030536448 hasConcept C204232928 @default.
• W2030536448 hasConcept C2776235491 @default.
• W2030536448 hasConcept C2776490512 @default.
• W2030536448 hasConcept C2777546739 @default.
• W2030536448 hasConcept C2779013556 @default.
• W2030536448 hasConcept C2780192828 @default.
• W2030536448 hasConcept C2781182431 @default.
• W2030536448 hasConcept C71924100 @default.
• W2030536448 hasConcept C87874733 @default.
• W2030536448 hasConceptScore W2030536448C121608353 @default.
• W2030536448 hasConceptScore W2030536448C126322002 @default.
• W2030536448 hasConceptScore W2030536448C142724271 @default.
• W2030536448 hasConceptScore W2030536448C193270364 @default.

• next